This presentation and any documents incorporated by reference may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may also include projections that are based on other projections. While we believe these assumptions and projections are reasonable and sound, as of the date hereof, actual results may ...

Core Insights - Pulse Biosciences, Inc. has initiated the NANOCLAMP AF Study for treating atrial fibrillation, marking a significant step in its clinical research efforts [1] Company Developments - The first patient has been enrolled in the NANOCLAMP AF Study, with the procedure successfully completed at St. Helena Hospital in California [1] - The procedure utilized the nPulse™ Cardiac Surgical System, which is based on the company's proprietary Nanosecond Pulsed Field Ablation™ technology [1] - The company recently received FDA approval, which supports the advancement of its innovative treatment approach [1]

Core Insights - Pulse Biosciences, Inc. announced late-breaking clinical study results from its nPulse™ Cardiac Surgical System during the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark [1] Company Overview - Pulse Biosciences is leveraging its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology [1] Clinical Study Details - The feasibility study aims to assess the initial safety and effectiveness of the nPulse™ technology in a first-in-human context [1]